FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 01:13:24 25/06/2024 am IST | Pre-market 12:02:48 pm | |||
| 0.177 EUR | -5.35% |
|
0.177 | 0.00% |
| Current month | -15.71% | ||
| 1 month | -16.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 0.177 | -5.35% |
| 21/24/21 | 0.187 | +0.54% |
| 20/24/20 | 0.186 | -2.11% |
| 19/24/19 | 0.19 | 0.00% |
| 18/24/18 | 0.19 | +5.56% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 01:13 am IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD33DU |
| ISIN | DE000MD33DU7 |
| Date issued | 31/03/2022 |
| Strike | 593.7 $ |
| Maturity | Unlimited |
| Parity | 621.32 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.48 € |
|---|---|
| Lowest since issue | 0.16 € |
| Spread | 0.002 € |
| Spread % | 1.12% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
464
USD
Spread / Average Target
-2.31%
- Stock Market
- Certificates
- Certificat
